Antibody · 혈액암 (AML/ALL)

166개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved166 programs
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
AntibodyLimited DatastaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#Biogen
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#MetastaticSolidTumor+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

HER2 Positive Early or Locally Advanced Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#HER2PositiveEarlyorLocallyAdvanc+1
Trials 1Status Active
AntibodyLimited DatastaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Hunan
Trials 1Status Active
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 3

Inotuzumab (Inotuzumab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase3#monoclonal-antibody#Pfizer
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

Intrathecal Rituximab (Intrathecal Rituximab)

Leukemia; Lymphoid Malignancies · Leukemia

#Leukemia#Antibody#Phase2#monoclonal-antibody#LymphoidMalignancies+1
Trials 1Status Discontinued

5 / 9 pages

← PreviousNext →